SCHEMBL17825942

SCHEMBL17825942

OC[C@H]1O[C@@H](n2cnc3c(NCc4c(O)cccc4I)ncnc32)[C@@H](O)[C@@H]1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 3/20 0.74
ADORA3 P0DMS8 6/20 0.71
ADORA2A P29274 3/20 0.71
ADORA1 P30542 3/20 0.71
ADORA2B P29275 1/20 0.71
TP53 P04637 3/20 0.69
SLC29A1 Q99808 3/20 0.69
TDP1 Q9NUW8 1/20 0.69
PRKAG1 P54619 1/20 0.68
PRKAA1 Q13131 1/20 0.68
PRKAB1 Q9Y478 1/20 0.68
SMN1; SMN2 Q16637 1/20 0.66
MITF O75030 1/20 0.66
LMNA P02545 1/20 0.66
TSHR P16473 1/20 0.65
NFKB1 P19838 1/20 0.65
STAT6 P42226 1/20 0.65
GMNN O75496 1/20 0.65
BLM P54132 1/20 0.65
PMP22 Q01453 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL637866 1.00 PAX8 (0.74) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL637865 1.00 PAX8 (0.74) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL639020 0.94 PAX8 (0.81) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL639019 0.94 PAX8 (0.81) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL19583103 0.94 PAX8 (0.81) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL638533 0.89 PAX8 (0.74) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL639997 0.89 PRKAG1 (0.70) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL19582951 0.89 PAX8 (0.74) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL638532 0.89 PAX8 (0.74) PAX8ADORA3ADORA2AADORA1ADORA2B
SCHEMBL639308 0.89 ADORA3 (0.76) PAX8ADORA3ADORA2AADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3229771-B1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIV PALACKEHO (CZ) 2024-04-03 EP claimed
EP-3229772-B1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIV PALACKEHO (CZ) 2020-04-29 EP claimed
US-10550144-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-02-04 US claimed
US-10100077-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2018-10-16 US claimed
US-20170334943-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-23 US claimed
US-20170326168-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-16 US claimed
EP-3229772-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF Univerzita Palackého v Olomouci (CZ) 2017-10-18 EP claimed
WO-2016091236-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2016-06-16 WO claimed
EP-3229771-B1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIV PALACKEHO (CZ) 2024-04-03 EP disclosed
EP-3229772-B1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIV PALACKEHO (CZ) 2020-04-29 EP disclosed
US-10550144-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-02-04 US disclosed
US-10100077-B2 6-aryl-9-glycosylpurines and use thereof UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2018-10-16 US disclosed
US-20170334943-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-23 US disclosed
US-20170326168-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2017-11-16 US disclosed
EP-3229772-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF Univerzita Palackého v Olomouci (CZ) 2017-10-18 EP disclosed
WO-2016091236-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326168-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF GART, DAO, GLA PAX8 4070/4885ADORA3 553/4885ADORA2A 355/4885
US-10550144-B2 6-aryl-9-glycosylpurines and use thereof GART, DAO, GLA PAX8 4070/4885ADORA3 553/4885ADORA2A 355/4885
US-20170334943-A1 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF UNG, FUT6, GART PAX8 3745/4885ADORA3 387/4885ADORA2A 256/4885
US-10100077-B2 6-aryl-9-glycosylpurines and use thereof UNG, FUT6, GART PAX8 3745/4885ADORA3 387/4885ADORA2A 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.